SIMON HOLLIDAY

Dr. Simon Holliday has been a rural general practitioner in NSW for over 2 decades. He is also a part-time Staff Specialist in Drug and Alcohol Clinical services at the Manning Hospital, Taree NSW and is chair of the pain management network of the Royal Australian College of General Practitioners Specific Interests faculty. He has explored the management of pain and dependency in general practice as prinicpal author in opinion pieces and research studies. 
  








DAVID JUURLINK

Dr. David Juurlink is an internal medicine specialist and Head of the Division of Clinical Pharmacology and Toxicology at Sunnybrook Health Sciences Centre in Toronto. He is also a Medical Toxicologist at the Ontario Poison Centre and a Senior Scientist at the Institute for Clinical Evaluative Sciences. He has received degrees in Pharmacy and Medicine from Dalhousie University, followed by postgraduate training in Internal Medicine, a residency in Clinical Pharmacology, a fellowship in Medical Toxicology and a PhD in Clinical Epidemiology all at the University of Toronto. In addition to his clinical and administrative roles, he is the Principal Investigator of the Canadian Drug Safety and Effectiveness Network and maintains an active research program in the field of drug safety, the clinical consequences of drug-drug interactions and the epidemiology of suicide and parasuicide.


IAIN MCGREGOR

Iain McGregor is Professor of Psychopharmacology, NHMRC Principal Research Fellow and Director of the Psychopharmacology Laboratory at the University of Sydney. 

Iain's research focuses on the effects of recreational drugs and prescription drugs on brain and behaviour and also involves development of new medications for the treatment of various diseases. His research spans medicinal chemistry, the use of cellular assays and preclinical animal models of disease, and also clinical trials in humans.

Major recent areas of research interest include the beneficial effects of oxytocin on social behaviour, the development of novel treatments for addiction-related and mental health problems, and tracking Australia’s increasing use of prescription psychotropic drugs.

Iain is a leading international expert in the area of cannabis and the cannabinoids and is preclinical director of the new Lambert Initiative at the University of Sydney: a $33.7 million philanthropic gift to fast track research into the therapeutic benefits of cannabinoids in various disease states.

Iain also has an interest in synthetic cannabinoids and published his first paper on this topic in 1996. He is currently funded by the NHMRC, along with Professor Michael Kassiou and Professor Mark Connor, to evaluate the toxicity of recently emerging synthetic cannabinoid compounds and to elucidate the mechanisms underlying their unpredictable effects.

PETER SAUL 

Dr. Peter Saul is a senior specialist in intensive care at John Hunter Hospital in Newcastle, and Director of Intensive Care at Newcastle Private Hospital. He is a founder of the Clinical Unit in Ethics and Health Law at the University of Newcastle, and advises the NSW Ministry of Health through the Clinical Ethics Advisory Panel. He has an interest in end of life, and has been involved in writing all the current NSW guidelines on end of life care and advance care planning. Current research interests include the provision of ethics support in health care and the management of dying in acute care.